Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM4GXW3)

• Drug Name: Ataluren Drug Info
• Synonyms: Ataluren; 775304-57-9; PTC124; 3-(5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl)benzoic acid; PTC-124; 3-[5-(2-Fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid; PTC124 (Ataluren); PTC 124; UNII-K16AME9I3V; Ataluren (PTC124); K16AME9I3V; NCGC00168759-02; Translarna; AK-31904; Benzoic acid, 3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]-; DSSTox_CID_26776; DSSTox_RID_81895; DSSTox_GSID_46776; Benzoic acid, 3-(5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl)-; CAS-775304-57-9; Ataluren [USAN:INN]; Translarna (TN); PTC124,Ataluren; Ataluren(ptc124)

Indication

Disease Entry	ICD 11	Status	REF
Cystic fibrosis	CA25	Phase 3	[1]
Dravet syndrome	8A61.11	Phase 2	[2]
Muscular dystrophy	8C70	Phase 2	[2]
Aniridia	LA11.3	Phase 1	[1]
Mucopolysaccharidosis	5C56.3	Phase 1	[1]
Duchenne dystrophy	8C70	Application submitted	[2]

• Cross-matching ID:
  PubChem CID: 11219835
  ChEBI ID: CHEBI:94805
  CAS Number: CAS 775304-57-9
  TTD Drug ID: DM4GXW3
  INTEDE Drug ID: DR0149

Molecule-Related Drug Atlas

Drug(s) Metabolized By UDP-glucuronosyltransferase 1A9 (UGT1A9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[5]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[6]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[7]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[8]
Mycophenolate mofetil	DMPQAGE	Hepatosplenic T-cell lymphoma		Approved	[9]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[8]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[8]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[10]
Nateglinide	DMLK2QH	Diabetic complication	5A2Y	Approved	[8]
Haloperidol	DM96SE0	Delirium		Approved	[8]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dystrophin nonsense mutant (DMD)	TT2TNRM	DMD_HUMAN	Modulator	[3]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
UDP-glucuronosyltransferase 1A9 (UGT1A9) Main DME	DE85D2P	UD19_HUMAN	Substrate	[4]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7341).
• [4] Ataluren pharmacokinetics in healthy Japanese and Caucasian subjects. Clin Pharmacol Drug Dev. 2019 Feb;8(2):172-178.
• [5] Polymorphic expression of UGT1A9 is associated with variable acetaminophen glucuronidation in neonates: a population pharmacokinetic and pharmacogenetic study. Clin Pharmacokinet. 2018 Oct;57(10):1325-1336.
• [6] Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005 Jul;33(7):1027-35.
• [7] Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Invest New Drugs. 2011 Dec;29(6):1511-4.
• [8] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [9] The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 2011 Jan;50(1):1-24.
• [10] The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene. J Biol Chem. 2003 Apr 18;278(16):13975-83.